Notice
Prof. Jernej Ule - How do protein-RNA condensates form and contribute to disease?
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
Descriptif
Mutations in many genes encoding RNA-binding proteins (RBPs) cause neurologic diseases, and especially the amyotrophic lateral sclerosis (ALS). These mutations tend to be located within intrinsically disordered regions (IDRs) of RBPs. To understand how these mutations act, we developed crosslinking and Immunoprecipitation (CLIP) to obtain transcriptome-wide maps of in vivo protein-RNA interactions. I will also describe our recent technical advances that helped us to use CLIP in a quantitative manner and to gain broader insights from analyses of public data. We developed an improved individual nucleotide resolution CLIP protocol (iiCLIP), which produces highly sensitive and specific data, and thus enables quantitative comparisons of interactions across conditions (Lee et al., 2021). Finally, I will exemplify how these advances helped with studies of mutations in the IDR of TDP-43, a protein that is a central factor in ALS and several other neurodegenerative diseases. CLIP enabled us to disentangle the principles driving the condensation of TDP-43 on cellular RNAs, which showed that the IDR selectively fine-tunes the RNA binding properties and functions of the protein (Hallegger et al., 2021). I'll also discuss how insights into the specificity of RBP condensation open new doors for understanding of protein-RNA complexes as mediators of signalling, disease and evolution.
Reference:
Lee, F.C.Y., Chakrabarti, A.M., Hänel, H., Monzón-Casanova, E., Hallegger, M., Militti, C., Capraro, F., Sadée, C., Toolan-Kerr, P., Wilkins, O., et al. (2021). An improved iCLIP protocol. bioRxiv, doi.org/10.1101/2021.08.27.457890
Thème
Dans la même collection
-
Dr Lori L. Isom - Dancing to a different tune: TANGO offers a precision medicine approach to treati…
Dravet syndrome is an intractable developmental and epileptic encephalopathy caused largely by de novo variants in SCN1A resulting in haploinsufficiency of the voltage-gated sodium channel α subunit
-
Prof. Michelle L. Hastings - Antisense Oligonucleotides for the Treatment of Disease
Antisense oligonucleotides (ASOs) have proven to be an effective therapeutic platform for the treatment of disease.
-
Dr Ana Cristina Calvo - Peripheral RNA Biomarkers in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown origin that causes progressive muscle paralysis and motor neuron death.
-
Prof. Antonella Riccio - RNA metabolism in developing neurons
Neurons are cells with a complex morphology, which maintain their cellular structure through the compartmentalized expression of proteins essential for growth and plasticity.
-
Dr Débora Lanznaster - Combined Metabolomics and targeted-transcriptomics analysis in the muscle of…
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons, leading to paralysis and death of patients after 3-5 years of symptoms’ onset
-
Director Jason Potter - What matters for making highly expressed mRNA.
The need for high quality mRNA for therapeutic applications has grown substantially over the last few years due to the efficacy of the COVID mRNA vaccines.
-
Dr Horacio Cabral - RNA/Polymer-Based Supramolecular Approaches for mRNA Delivery
Messenger RNA (mRNA) therapeutics are attracting much attention, particularly after the approval of two mRNA vaccine formulations for COVID-19.
-
Prof. Krzystof Sobczak - Compounds which alleviate the pleiotropic toxicity of RNA harboring expand…
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an incurable neurodegenerative disorder caused by expansion of CGG repeats in the FMR1 5'UTR.
-
Prof. Steven Dowdy - Delivery of RNA Therapeutics: The Great Endosomal Escape!
All macromolecular therapeutics, including ASOs, siRNAs, peptides, proteins, CRISPR, mRNA and non-viral DNA vectors, are taken up into cells by endocytosis.
-
Dr Liliane Massade - Squalenoyl siRNA PMP22 nanoparticles, a potent therapy for Charcot-Marie-Tooth…
Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication in chromosome 17, results in peripheral myelin protein 22 (Pmp22) over-expression and axon demyelination.
-
Prof. Stefano Gustincich - Antisense long non-coding SINEUP RNAs: from molecular mechanism to thera…
Natural SINEUPs are antisense long non-coding RNAs that enhance translation of sense mRNAs. Their activity depends on the combination of two domains: the overlapping region, or binding domain (BD),